| Date | Title | | | 11/20/08 | Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference| LIVE AUDIO WEBCAST TUESDAY, DECEMBER 2, 2008
SAN DIEGO, Nov. 20 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief
Executive Officer of Neurocrine Biosciences will be presenting at the 20th
Annual Piper Jaffray Health Care Conference in New York.
The live "fireside chat" presentation takes place Tuesday, December 2,
2008 at 1:30 p.m. Eastern Time (ET) /10:30 a.m. Pacific Time (PT). The
p... |
|  | | 10/28/08 | Neurocrine Biosciences Reports Third Quarter 2008 Results| SAN DIEGO, Calif., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the
quarter ended September 30, 2008. For the third quarter of 2008, the Company
reported a net loss of $17.7 million, or $(0.46) per share compared with a net
loss of $27.2 million, or $(0.72) per share, for the same period in 2007. For
the nine months, the Company reported a net loss of $59.8 million, or $(1.56)
per share,... |
| | | 10/28/08 | Webcast Alert: Neurocrine Announces 3Q 08 Financial Results| SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences
(Nasdaq: NBIX) announces the following Webcast:
What: Neurocrine Biosciences 3rd Quarter 2008 Financial Results
When: October 28, 2008 @ 5 p.m. Eastern 2 p.m. Pacific
Where: http://www.videonewswire.com/event.asp?id=52783
How: Live over the Internet -- Simply log on to the web at the address
above.
Contact: Claudia Woodworth, 858-617-7759
If you are unab... |
| | | 10/27/08 | Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference| LIVE AUDIO WEBCAST TUESDAY, NOVEMBER 4, 2008
SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief
Executive Officer of Neurocrine Biosciences will be presenting at the
Oppenheimer 19th Annual Healthcare Conference in New York.
The live presentation takes place Tuesday, November 4, 2008 at 10:00 a.m.
Eastern Time (ET) /7:00 a.m. Pacific Time (PT). The presentation will be
... |
| | | 10/22/08 | Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results| CONFERENCE CALL AND WEBCAST SCHEDULED FOR TUESDAY, OCTOBER 28
SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report its third quarter
2008 financial results after the Nasdaq market closes on Tuesday, October 28,
2008. Neurocrine will host a live conference call and webcast to discuss its
financial results and provide a Company update Tuesday afternoon, October 28,
2008 at 5:00 p.m. Eastern Time (2:00 p.m. P... |
| | | 09/22/08 | Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference| Live Audio Webcast Thursday, September 25, 2008
SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief
Executive Officer of Neurocrine Biosciences will be presenting at the UBS
Global Life Sciences Conference at the Grand Hyatt in New York.
The live presentation takes place Thursday, September 25, 2008 at
10:00 a.m. Eastern Time (ET) /7:00 a.m. Pacific Time (PT). The presentatio... |
| | | 09/02/08 | Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis| Phase II Study Meets Primary Bone Mineral Density and Secondary Efficacy Endpoints Company to Host Conference Call and Webcast Wednesday, September 3rd at 8:30 am ET / 5:30 am PTSAN DIEGO, Sept 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced positive safety and efficacy results from its
third Phase II clinical trial using its proprietary, orally-active nonpeptide
Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, e... |
| | | 08/25/08 | Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference| COMPANY PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS IN
THE BIOTECH INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH
SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief
Executive Officer will be presenting at both the Thomas Weisel Healthcare
Conference in Boston and the NewsMakers in the Biotech Industry Conference in
New York.
The presentation at the Thomas Wei... |
| | | 07/30/08 | Neurocrine Biosciences Reports Second Quarter 2008 Results| SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced its financial results for the quarter ended
June 30, 2008. For the second quarter of 2008, the Company reported a net loss
of $21.0 million, or $(0.55) per share compared with a net loss of $26.4
million, or $(0.69) per share, for the same period in 2007. For the six
months, the Company reported a net loss of $42.0 million, or $(1.10) per
share, as compared to $52.1 million, or $(1.... |
| | | 07/23/08 | Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results| Conference Call and Webcast Scheduled for Wednesday, July 30
SAN DIEGO, July 23 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report its second quarter
2008 financial results after the Nasdaq market closes on Wednesday, July 30,
2008. Neurocrine will host a live conference call and webcast to discuss its
financial results and provide a Company update Wednesday afternoon, July 30,
2008 at 5:00 p.m. Eastern Time (2:00... |
| | | 06/17/08 | Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis| STUDY TO ASSESS IMPACT OF ELAGOLIX ON BONE MINERAL DENSITY
SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the elagolix 0603 Phase IIb trial (Petal
Study) has completed the 6-month treatment phase. The last subject completed
her Week 24 study visit in early June. This Phase IIb trial assesses the
impact of elagolix treatment on bone mineral density (BMD) as the primary
endpoint using Dual Energy X-ray Absorptiometr... |
| | | 05/12/08 | Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference| Live Audio Webcast Thursday, May 22, 2008
SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that Neurocrine Biosciences will present at the
Citi Investment Research Global Health Care Conference at the Hilton New York.
The live presentation takes place Thursday, May 22, 2008 at 3:00 p.m. Eastern
Time (ET) /12:00 p.m. Pacific Time (PT). The presentation will be
simultaneously webcast and may be accessed on the Compa... |
| | | 04/30/08 | Neurocrine Biosciences Reports First Quarter 2008 Results| SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced its financial results for the quarter ended
March 31, 2008. For the first quarter of 2008, the Company reported a net loss
of $21.1 million, or $(0.55) per share compared with a net loss of $25.7
million, or $(0.68) per share, for the same period in 2007.
Revenues for the first quarter of 2008 were $1.8 million compared with
$0.1 million for the same period last year. The incre... |
| | | 04/30/08 | Webcast Alert: Neurocrine Announces 1Q08 Financial Results| SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Neurocrine Biosciences
(Nasdaq: NBIX) announces the following Webcast:
What: Neurocrine Announces 1Q08 Financial Results
When: Wednesday, April 30, 2008 at 5:00PM ET / 2:00PM PT
Where: http://www.videonewswire.com/event.asp?id=47931
How: Live over the Internet -- Simply log on to the web at the
address above.
Contact: Claudia Woodworth of Neurocrine Biosciences, 8... |
| | | 04/21/08 | Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results| CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, APRIL 30
SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report its first quarter
2008 financial results after the Nasdaq market closes on Wednesday, April 30,
2008. Neurocrine will host a live conference call and webcast to discuss its
financial results and provide a Company update Wednesday afternoon, April 30,
2008 at 5:00 p.m. Eastern Time (2:00 p.m. ... |
| | | 02/05/08 | Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results| SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced its financial results for the fourth quarter
and year ended December 31, 2007. For the three months ended December 31,
2007, the Company reported a net loss of $128.0 million or $3.35 loss per
share compared to a net loss of $14.7 million or $0.39 loss per share for the
same period last year. For the year ended December 31, 2007, the Company had a
net loss of $207.3 million, or $5.45... |
| | | 01/24/08 | Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results| Conference Call and Webcast Scheduled for Tuesday, February 5
SAN DIEGO, Jan. 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that the Company will report its fourth quarter
and year-end 2007 financial results after the Nasdaq market closes on Tuesday,
February 5, 2008. Neurocrine will then host a live conference call and webcast
to discuss its financial results and provide a Company update Tuesday
afternoon, February 5, 2008 at 5:00 p.m... |
| | | 01/14/08 | Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer| SAN DIEGO, Jan. 14 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) announced today that Kevin Gorman, Ph.D., Neurocrine's Chief
Operating Officer has been appointed President and Chief Executive Officer and
a member of the Board of Directors of Neurocrine Biosciences. Gary Lyons will
step down as President and Chief Executive Officer of Neurocrine and will
continue to serve as a member of the Board of Directors.
"While this was a very difficult decision for m... |
| |
|
